Published in Clin Cancer Res on March 15, 2007
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. PLoS One (2013) 1.55
Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing g protein-coupled receptor 7) splice variants from human fetal membranes. Endocrinology (2007) 1.04
Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch (2009) 0.99
International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev (2015) 0.97
Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cells. Endocrinology (2008) 0.89
Elevated serum levels of human relaxin-2 in patients with esophageal squamous cell carcinoma. World J Gastroenterol (2013) 0.86
Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes (2013) 0.86
Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation. Br J Pharmacol (2012) 0.86
Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol (2016) 0.84
Role of relaxin-2 in human primary osteosarcoma. Cancer Cell Int (2013) 0.81
Structural commonality of C1q TNF-related proteins and their potential to activate relaxin/insulin-like family peptide receptor 1 signalling pathways in cancer cells. Br J Pharmacol (2016) 0.81
Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer (2011) 0.81
Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain. Clin Exp Metastasis (2013) 0.80
RegNetB: predicting relevant regulator-gene relationships in localized prostate tumor samples. BMC Bioinformatics (2011) 0.80
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer (2009) 0.80
Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci (2009) 0.79
Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res (2008) 0.79
Disturbed relaxin signaling pathway and testicular dysfunction in mouse offspring upon maternal exposure to simazine. PLoS One (2012) 0.78
G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention. Hum Reprod Update (2016) 0.78
Relaxin-2 expression in temporal bone carcinoma. Eur Arch Otorhinolaryngol (2014) 0.77
RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance. Biomed Res Int (2015) 0.76
RXFP1 is Targeted by Complement C1q Tumor Necrosis Factor-Related Factor 8 in Brain Cancer. Front Endocrinol (Lausanne) (2015) 0.75
Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside. Br J Pharmacol (2016) 0.75
Discovering Pair-wise Synergies in Microarray Data. Sci Rep (2016) 0.75
Relaxin-like peptides in male reproduction - a human perspective. Br J Pharmacol (2016) 0.75
Relaxin confers cytotrophoblast protection from hypoxia-reoxygenation injury through the phosphatidylinositol 3-kinase-Akt/protein kinase B cell survival pathway. Am J Physiol Regul Integr Comp Physiol (2017) 0.75
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res (2006) 3.58
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Perineural invasion in cancer: a review of the literature. Cancer (2009) 3.06
Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol (2009) 3.04
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res (2004) 2.75
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res (2005) 2.14
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res (2003) 2.01
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A (2011) 1.94
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res (2006) 1.90
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res (2002) 1.89
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Rethinking dog domestication by integrating genetics, archeology, and biogeography. Proc Natl Acad Sci U S A (2012) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res (2004) 1.77
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol (2007) 1.62
High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol (2004) 1.61
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther (2006) 1.57
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood (2011) 1.56
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res (2008) 1.56
Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys (2006) 1.55
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res (2008) 1.54
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res (2007) 1.53
Intraoperative consultation for renal lesions. Implications and diagnostic pitfalls in 324 cases. Am J Clin Pathol (2003) 1.52
Pseudoglandular (adenoid, acantholytic) penile squamous cell carcinoma: a clinicopathologic and outcome study of 7 patients. Am J Surg Pathol (2009) 1.51
The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res (2004) 1.51
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2013) 1.43
Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer (2009) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther (2006) 1.38
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res (2007) 1.34
Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol (2007) 1.33
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res (2006) 1.31
Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem (2006) 1.31
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (2008) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
Mutations of the GREAT gene cause cryptorchidism. Hum Mol Genet (2002) 1.27
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res (2004) 1.25
Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate (2005) 1.24
Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res (2006) 1.24
Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res (2003) 1.22
Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res (2011) 1.21
Allele-specific methylation of a functional CTCF binding site upstream of MEG3 in the human imprinted domain of 14q32. Chromosome Res (2005) 1.20
GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Mol Endocrinol (2003) 1.20
Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res (2010) 1.18
Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res (2006) 1.17
Notch and TGFβ form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell (2012) 1.16
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res (2003) 1.16
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res (2006) 1.16
Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One (2012) 1.15
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer (2008) 1.15
FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res (2013) 1.14
Cryptorchidism in mice with an androgen receptor ablation in gubernaculum testis. Mol Endocrinol (2012) 1.14
Penile squamous cell carcinoma clinicopathological features, nodal metastasis and outcome in 333 cases. J Urol (2009) 1.12
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res (2007) 1.11
Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol (2006) 1.10
Genetic targeting of relaxin and insulin-like factor 3 receptors in mice. Endocrinology (2004) 1.10
Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res (2003) 1.09
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol (2010) 1.07
FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res (2011) 1.07
INPP4B: the new kid on the PI3K block. Oncotarget (2011) 1.07
Developments in the pathology of penile squamous cell carcinomas. Urology (2010) 1.07
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate (2005) 1.06
Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate (2006) 1.06
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther (2010) 1.04
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther (2010) 1.04